← Back to Search

18F-Clofarabine PET Imaging for Cancer

Phase < 1

Recruiting

Led By Roberto Vargas, MD

Research Sponsored by Roberto Vargas

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Over 18 years of age

Patient is able to remain still for the duration of the imaging procedure (up to one hour)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 60 minutes after cfa pet

Awards & highlights

No Placebo-Only Group

Summary

This trial will test whether a new imaging agent, 18F-Clofarabine, can be used to show pyrimidine metabolism in order to better predict whether cancer drugs will be effective.

Who is the study for?

This trial is for adults over 18 with metastatic carcinoma or adenocarcinoma, confirmed by imaging. Participants must have measurable disease, be able to stay still for an hour during imaging, and have normal organ function levels. It's not suitable for those with recent severe heart issues, significant bleeding, stroke risks, or pregnant/breastfeeding women.

What is being tested?

The study tests if a new PET/CT imaging agent called 18F-Clofarabine (CFA) can effectively image cancer metabolism related to pyrimidine metabolism—a factor in how well certain cancer drugs work.

What are the potential side effects?

Specific side effects of the PET imaging agent are not detailed here but generally include potential allergic reactions to the tracer substance and discomfort from remaining still during the procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am over 18 years old.

Select...

I can stay still for up to an hour for a scan.

Select...

My cancer is confirmed as carcinoma or adenocarcinoma.

Select...

My cancer has spread and this was confirmed by a CT scan.

Select...

I am fully active or can carry out light work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 60 minutes after cfa pet

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 60 minutes after cfa pet

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 60 minutes after cfa pet for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Evaluate CFA as a PET imaging agent

Secondary study objectives

Adverse Events

Correlate CFA uptake with OS

Correlate CFA uptake with PFS

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: 18F-ClofarabineExperimental Treatment1 Intervention

18F-Clofarabine as PET imaging agent for measuring the activity of deoxycytidine kinase (DCK) in various normal and abnormal tissues in cancer participants before and after therapy

0 / 5Eligibility criteria met